Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M

Personalis, Inc.

2024-Q1 EPS reported -$0.26 revenue$19,525,000

Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.
Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.
Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.
Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.
NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Personalis, Inc. reported first quarter of 2024 ended March 31, 2024 results: revenue total company revenue of $19.5 million, net income Net loss of $13.0 million. Guidance raised.

Period: first quarter of 2024 ended March 31, 2024
Revenue: total company revenue of $19.5 million
Net income: Net loss of $13.0 million
Guidance: raised
Result: reported results

Exact text from the filing

delivered in Q1, reflecting 100% engagement of NeXT Personal Dx early access clients and strong NeXT Dx growth. “We began 2024 with strong execution as we delivered revenue of $19.5 million in the first quarter, exceeding the upper-end of our guidance range, and we continue to develop compelling NeXT Personal clinical evidence as we work towards obtaining Medicare

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.